SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

OCUL

Ocular Therapeutix, Inc.
BEARISH
Impact 5/10
Horizonmonths Processed7d 17h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Monitor the AXPAXLI NDA submission in Q4 2026 and the FDA's acceptance decision. The SOL-R interim Week 52 safety analysis in Q4 2026 will be a key catalyst. Cash runway into 2028 provides a long development horizon, but the widening net loss and rising R&D spend warrant attention to cash burn rate.

DirectionBearish
Confidencehigh
Horizonmonths

OTX-TKI

▲ Bullish Named in this press release
Impact
Phase
Phase 3 (pivotal completed; NDA submission imminent)
Time to market
If the NDA is submitted in Q4 2026 as planned, a standard FDA review would take approximately 10 months, suggesting a potential approval decision in late 2027. A priority review (possible under 505(b)(2) pathway) could shorten this to 6-8 months, potentially yielding a mid-2027 decision.
Next catalyst
None dated

What to watchWatch for the NDA submission announcement, expected any week given the Q4 2026 timeline confirmed on the November 9 earnings call. After submission, the next catalysts are FDA acceptance (60-day filing review) and PDUFA date assignment. A standard review would set a decision in late 2027; a priority review could accelerate to mid-2027. The stock's wide gap between current price ($6.85) and analyst targets ($25.45 mean) reflects both the binary regulatory risk and the potential for significant upside if the NDA is accepted and reviewed favorably.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$6.85
T+0 close · Nov 9, 2026 · via day close
Latest settled
−12.26%
T+5 · $6.01
Vs SPY
−10.57%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $6.85entry
  2. T+1 · 7d ago −3.50%α −3.14% · $6.61
  3. T+5 · 18h ago −12.26%α −10.57% · $6.01
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocular Therapeutix reported Q3 2026 net loss of $(0.42) per share on revenue of $12.9M, missing the consensus EPS estimate of $(0.35) and revenue estimate of $14.3M. The company reiterated its AXPAXLI NDA submission for wet AMD is on track for Q4 2026, with $530.6M cash providing runway into 2028.

Key Financial Metrics

EPS
−$0.42
est −$0.35 · -20.0%
Revenue
$12.9M
est $14.3M · -9.8% · -11.5% YoY
Rating
miss

Key Facts

  • Q3 2026 net loss $(94.8)M or $(0.42)/share vs consensus $(0.35)/share
  • Q3 2026 total revenue $12.9M vs consensus $14.3M and prior year $14.5M
  • Cash balance $530.6M as of Sep 30, 2026, expected runway into 2028
  • AXPAXLI NDA submission for wet AMD on track for Q4 2026 under 505(b)(2) pathway
  • SOL-R primary endpoint moved to Week 40; topline results expected Q1 2028
  • R&D expenses $74.8M in Q3 2026 vs $52.4M in Q3 2025, up 42.8%
  • Selling and marketing expenses $15.7M vs $13.1M in prior year quarter

Financial Impact

EPS miss of $(0.42) vs $(0.35) consensus; revenue miss of $12.9M vs $14.3M consensus; net loss widened to $(94.8)M from $(69.4)M YoY

revenueepsnet losscash burn

Risk Factors

  • AXPAXLI NDA may not be accepted for filing or may not receive FDA approval
  • SOL-R trial design changes and interim safety analysis could introduce uncertainty
  • Rising R&D and SG&A expenses are accelerating cash burn despite $530.6M balance
  • Revenue decline from DEXTENZA product sales may continue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398240

Track record

20 reports on OCUL

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
  2. Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
  3. Nov 9, 20267d ago Press Release Bearish 5/10 Viewing Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
  4. Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
  6. Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
  7. Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
  8. Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
  9. Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
  10. Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 8h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026